Mesothelin SS-(dsFv)-PE38

Drug Profile

Mesothelin SS-(dsFv)-PE38

Alternative Names: Mesothelin Mab; Mesothelium Antigen Therapy - NeoPharm; SS(dsFv) PE38; SS1-PE38

Latest Information Update: 11 Nov 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer National Cancer Institute (USA); NeoPharm Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Head and neck cancer; Mesothelioma; Ovarian cancer

Most Recent Events

  • 31 Oct 2002 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 31 Oct 2002 Discontinued - Phase-II for Mesothelioma in USA (unspecified route)
  • 31 Oct 2002 Discontinued - Preclinical for Head and neck cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top